Technical Analysis for NERV - Minerva Neurosciences, Inc
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical NERV trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 18 | 20 DMA Support | Bullish | 0.00% |
| Jan 16 | NR7 | Range Contraction | -1.94% |
| Jan 15 | Overbought Stochastic | Strength | -0.98% |
| Jan 15 | Down 3 Days in a Row | Weakness | -0.98% |
| Jan 14 | Weak + Overbought | Other | -3.15% |
| Jan 14 | Overbought Stochastic | Strength | -3.15% |
| Jan 11 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -6.85% |
| Jan 11 | Spinning Top | Other | -6.85% |
| Jan 11 | NR7 | Range Contraction | -6.85% |
| Jan 11 | Weak + Overbought | Other | -6.85% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-05
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more NERV news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 12.95 |
| 52 Week Low | 5.0 |
| Average Volume | 151,832 |
| 200-Day Moving Average | 8.6368 |
| 50-Day Moving Average | 7.7452 |
| 20-Day Moving Average | 6.938 |
| 10-Day Moving Average | 7.315 |
| Average True Range | 0.4269 |
| ADX | 20.06 |
| +DI | 17.7237 |
| -DI | 20.003 |
| Chandelier Exit (Long, 3 ATRs ) | 6.4593 |
| Chandelier Exit (Short, 3 ATRs ) | 7.2707 |
| Upper Bollinger Band | 7.8281 |
| Lower Bollinger Band | 6.0479 |
| Percent B (%b) | 0.57 |
| BandWidth | 25.658691 |
| MACD Line | -0.1346 |
| MACD Signal Line | -0.218 |
| MACD Histogram | 0.0834 |
| Fundamentals | Value |
|---|---|
| Market Cap | 300.54 Million |
| Num Shares | 42.5 Million |
| EPS | -1.08 |
| Price-to-Earnings (P/E) Ratio | -6.55 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 2.36 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.48 | ||||
| Resistance 3 (R3) | 7.47 | 7.32 | 7.41 | ||
| Resistance 2 (R2) | 7.32 | 7.22 | 7.33 | 7.38 | |
| Resistance 1 (R1) | 7.20 | 7.16 | 7.13 | 7.21 | 7.36 |
| Pivot Point | 7.05 | 7.05 | 7.02 | 7.06 | 7.05 |
| Support 1 (S1) | 6.93 | 6.95 | 6.86 | 6.94 | 6.78 |
| Support 2 (S2) | 6.78 | 6.89 | 6.79 | 6.76 | |
| Support 3 (S3) | 6.66 | 6.78 | 6.73 | ||
| Support 4 (S4) | 6.67 |
